Cancer reports最新文献_第5页

Epidemiology of Soft Tissue Sarcoma in Iran: Four-Year National Cancer Registry Data Report (2014–2017) 伊朗软组织肉瘤流行病学：四年国家癌症登记数据报告（2014-2017）。

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-01-10 DOI: 10.1002/cnr2.70118

Mohammad Sajed Dehghan Banadaki, Vahid Rahmanian, Saeed Hosseini, Seyyed Mohammad Hossein Hosseini, Narjes Hazar

Introduction

An uncommon and diverse class of cancers originating from mesenchymal tissues is designated as soft tissue sarcoma (STS). To develop effective preventive and treatment strategies for STS, it is essential to gain a deeper understanding of the epidemiological trends associated with the disease. This research will analyze the 4-year age-standardized incidence rate (ASIR) and geographical distribution of STS in Iran in great detail.

Methods

The study population comprised 4968 cases of STS recorded in the Cancer Registry System between 2014 and 2017. The demographic data examined included gender, place of residence, and year of diagnosis. The age-standardized rate (ASR) of STS incidence was calculated for each location using the World Standard Population. The data were examined using the program ArcMap10.5. The geographic distribution of STS was investigated using the Moran test.

Results

The ASRs for STS in Iran from 2014 to 2017 were recorded as 1.25 (ASR in male: 1.47, ASR in female: 1.06), 1.36 (ASR in male: 1.46, ASR in female: 1.29), 1.37 (ASR in male: 1.52, ASR in female: 1.21), and 1.78 (ASR in male: 1.58, ASR in female: 1.98), respectively. In 2014 and 2015, age-standardized incidence at the national level showed a statistically significant regional dispersion that appeared as a clustering pattern, according to Moran's test. However, in 2016 and 2017, this dispersion failed to become statistically significant. Interestingly, men had a greater rate of STS incidence than females. As age grows, ASIR shows a steadily rising trend. The most important gains are shown in the 55–59 age group, which peaked at 4.535 in 2017, and the 80–84 age group, which peaked at 10.848 in the same year.

Conclusion

The incidence of STS in Iran is lower than the global average. The discrepancies in gender disparities, regional distribution, and incidence rates underscore the complexity of STSs. The findings of this study may assist healthcare professionals and policymakers in the development of region-specific plans for the treatment, early detection, and prevention of STSs.

摘要：软组织肉瘤（STS）是一种起源于间充质组织的罕见而多样的癌症。为了制定有效的STS预防和治疗策略，必须深入了解与该疾病相关的流行病学趋势。本研究将详细分析伊朗4岁年龄标准化发病率（ASIR）和STS的地理分布。方法：研究人群包括2014年至2017年癌症登记系统中记录的4968例STS病例。检查的人口统计数据包括性别、居住地和诊断年份。使用世界标准人口计算每个地区STS发病率的年龄标准化率（ASR）。使用ArcMap10.5程序检查数据。采用Moran检验调查STS的地理分布。结果：2014 - 2017年伊朗STS患者的ASR分别为1.25（男性：1.47，女性：1.06）、1.36（男性：1.46，女性：1.29）、1.37（男性：1.52，女性：1.21）、1.78（男性：1.58，女性：1.98）。根据莫兰的检验，2014年和2015年，全国层面的年龄标准化发病率在统计上显示出显著的区域分散，表现为聚类模式。然而，在2016年和2017年，这种差异在统计上没有显著性。有趣的是，男性的STS发病率高于女性。随着年龄的增长，ASIR呈稳步上升趋势。最重要的增长出现在55-59岁年龄组，2017年达到4.535岁的峰值，80-84岁年龄组在同年达到10.848岁的峰值。结论：伊朗STS发病率低于全球平均水平。性别差异、区域分布和发病率的差异凸显了性传播感染的复杂性。本研究结果可协助卫生保健专业人员和政策制定者制定地区性的性传播感染治疗、早期发现和预防计划。

{"title":"Epidemiology of Soft Tissue Sarcoma in Iran: Four-Year National Cancer Registry Data Report (2014–2017)","authors":"Mohammad Sajed Dehghan Banadaki, Vahid Rahmanian, Saeed Hosseini, Seyyed Mohammad Hossein Hosseini, Narjes Hazar","doi":"10.1002/cnr2.70118","DOIUrl":"10.1002/cnr2.70118","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>An uncommon and diverse class of cancers originating from mesenchymal tissues is designated as soft tissue sarcoma (STS). To develop effective preventive and treatment strategies for STS, it is essential to gain a deeper understanding of the epidemiological trends associated with the disease. This research will analyze the 4-year age-standardized incidence rate (ASIR) and geographical distribution of STS in Iran in great detail.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study population comprised 4968 cases of STS recorded in the Cancer Registry System between 2014 and 2017. The demographic data examined included gender, place of residence, and year of diagnosis. The age-standardized rate (ASR) of STS incidence was calculated for each location using the World Standard Population. The data were examined using the program ArcMap10.5. The geographic distribution of STS was investigated using the Moran test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The ASRs for STS in Iran from 2014 to 2017 were recorded as 1.25 (ASR in male: 1.47, ASR in female: 1.06), 1.36 (ASR in male: 1.46, ASR in female: 1.29), 1.37 (ASR in male: 1.52, ASR in female: 1.21), and 1.78 (ASR in male: 1.58, ASR in female: 1.98), respectively. In 2014 and 2015, age-standardized incidence at the national level showed a statistically significant regional dispersion that appeared as a clustering pattern, according to Moran's test. However, in 2016 and 2017, this dispersion failed to become statistically significant. Interestingly, men had a greater rate of STS incidence than females. As age grows, ASIR shows a steadily rising trend. The most important gains are shown in the 55–59 age group, which peaked at 4.535 in 2017, and the 80–84 age group, which peaked at 10.848 in the same year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The incidence of STS in Iran is lower than the global average. The discrepancies in gender disparities, regional distribution, and incidence rates underscore the complexity of STSs. The findings of this study may assist healthcare professionals and policymakers in the development of region-specific plans for the treatment, early detection, and prevention of STSs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short- and Long-Term Efficacy of Hyperbaric Oxygen Therapy in Irradiated Breast Cancer Patients With Long-Standing Lymphedema: A Prospective Case Series 高压氧治疗放疗后长期淋巴水肿乳腺癌患者的短期和长期疗效：前瞻性病例系列。

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-01-08 DOI: 10.1002/cnr2.70109

Imjai Chitapanarux, Siriarrayapa Chachvarat, Patumrat Sripan, Thienchai Pattarasakulchai, Nuttaya Pattamapaspong, Thanat Kanthawang, Montana Buntragulpoontawee

Background

Several studies have explored the advantage of treatment with hyperbaric oxygen (HBO) for upper extremity lymphedema in irradiated breast cancer patients and reported controversial results. This prospective case series aimed to document the short- and long-term efficacy of this therapy, focusing on the arm volume and functional assessment in breast cancer patients with a history of long-standing lymphedema for more than 2 years.

Case

Six breast cancer patients with long-standing lymphedema were enrolled. All of them received breast surgery and dissection of axillary lymph nodes, chemotherapy, and postoperative radiotherapy. The average duration from the onset of lymphedema to HBO treatment was 9 ± 5.92 years (range 2–17). All patients were treated for 90 min in the HBO chamber with 100% oxygen at a higher pressure of two times the atmospheric pressure, five times a week for 30 sessions. We measured the circumference of both arms and calculated the arm volume before treatment (baseline), after 30 sessions of treatment, and after treatment at 3, 6, and 24 months. Functional assessment focused on the ability of the arm, shoulder, and hand using the Thai Quick-DASH questionnaires, which were assessed by the patients at the same periods. The change of arm volume and Thai Quick-DASH score at each time point were compared to the starting point data before HBO.

Conclusion

The change of arm volume and mean Quick-DASH score had decreased at 3, 6, and 24 months after treatment compared to the starting point before HBO, However, these changes were not statistically significant.

背景：一些研究探讨了高压氧（HBO）治疗放射乳腺癌患者上肢淋巴水肿的优势，并报道了有争议的结果。该前瞻性病例系列旨在记录该疗法的短期和长期疗效，重点关注具有2年以上长期淋巴水肿病史的乳腺癌患者的手臂体积和功能评估。病例：6例长期淋巴水肿的乳腺癌患者。所有患者均接受乳房手术、腋窝淋巴结清扫、化疗及术后放疗。从淋巴水肿发病到高压氧治疗的平均时间为9±5.92年（范围2-17年）。所有患者均在高压氧室中进行90分钟的治疗，在两倍大气压的高压下使用100%氧气，每周5次，共30次。我们测量了治疗前（基线）、治疗30个疗程后以及治疗后3、6和24个月时的双臂周长并计算了双臂体积。功能评估的重点是手臂、肩膀和手的能力，使用泰国Quick-DASH问卷，由患者在同一时期进行评估。将各时间点手臂体积变化及Thai Quick-DASH评分与HBO前起始点数据进行比较。结论：治疗后3、6、24个月臂体积和平均Quick-DASH评分的变化与HBO治疗前相比有所下降，但变化无统计学意义。

{"title":"Short- and Long-Term Efficacy of Hyperbaric Oxygen Therapy in Irradiated Breast Cancer Patients With Long-Standing Lymphedema: A Prospective Case Series","authors":"Imjai Chitapanarux, Siriarrayapa Chachvarat, Patumrat Sripan, Thienchai Pattarasakulchai, Nuttaya Pattamapaspong, Thanat Kanthawang, Montana Buntragulpoontawee","doi":"10.1002/cnr2.70109","DOIUrl":"10.1002/cnr2.70109","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Several studies have explored the advantage of treatment with hyperbaric oxygen (HBO) for upper extremity lymphedema in irradiated breast cancer patients and reported controversial results. This prospective case series aimed to document the short- and long-term efficacy of this therapy, focusing on the arm volume and functional assessment in breast cancer patients with a history of long-standing lymphedema for more than 2 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>Six breast cancer patients with long-standing lymphedema were enrolled. All of them received breast surgery and dissection of axillary lymph nodes, chemotherapy, and postoperative radiotherapy. The average duration from the onset of lymphedema to HBO treatment was 9 ± 5.92 years (range 2–17). All patients were treated for 90 min in the HBO chamber with 100% oxygen at a higher pressure of two times the atmospheric pressure, five times a week for 30 sessions. We measured the circumference of both arms and calculated the arm volume before treatment (baseline), after 30 sessions of treatment, and after treatment at 3, 6, and 24 months. Functional assessment focused on the ability of the arm, shoulder, and hand using the Thai Quick-DASH questionnaires, which were assessed by the patients at the same periods. The change of arm volume and Thai Quick-DASH score at each time point were compared to the starting point data before HBO.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The change of arm volume and mean Quick-DASH score had decreased at 3, 6, and 24 months after treatment compared to the starting point before HBO, However, these changes were not statistically significant.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glomus Tumor in the Left Submandibular Region: A Rare Case Report and Literature Review 左侧下颌下区血管球瘤：一例罕见病例报告及文献复习。

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-01-07 DOI: 10.1002/cnr2.70113

Huan Liu, Chengyao Zhu

Background

Glomus tumors are rare, benign mesenchymal neoplasms predominantly located in subungual regions of the extremities. Their occurrence in the mandibular region is exceptionally uncommon, presenting unique diagnostic challenges. Only a limited number of submandibular glomus tumors have been documented, leaving their presentation and management largely underexplored.

Case

We presented a case of glomus tumor in the submandibular area of a 60-year-old female, which appeared as a purplish-red lesion. In the absence of characteristic symptoms such as tenderness and cold sensitivity, the lesion was initially misdiagnosed as a pigmented nevus. Histopathological analysis subsequently confirmed the diagnosis as a glomus tumor. Immunohistochemical (IHC) staining further confirmed the tumor's smooth muscle and mesenchymal origins, with positive for Vimentin, SMA, Syn, Actin, Desmin, and CD34. The patient underwent surgical tumor excision with no recurrence after 28 months of follow-up.

Conclusion

This case underscores the importance of considering glomus tumors in atypical locations and highlights the need for a comprehensive diagnostic approach to prevent misdiagnosis. Surgical excision remains the primary treatment, with extended postoperative surveillance recommended to monitor for recurrence.

背景：血管球瘤是一种罕见的良性间充质肿瘤，主要位于四肢的足下区域。他们的发生在下颌区域是非常罕见的，提出了独特的诊断挑战。只有数量有限的下颌球囊瘤已被记录，留下他们的表现和管理很大程度上未被探索。病例：我们报告了一个60岁女性下颌骨区域的血管球瘤，其表现为紫红色病变。由于没有压痛和冷敏感等特征性症状，病变最初被误诊为色素痣。组织病理学分析随后证实诊断为血管球瘤。免疫组化（IHC）染色进一步证实了肿瘤的平滑肌和间充质起源，Vimentin、SMA、Syn、Actin、Desmin和CD34阳性。患者行手术切除肿瘤，随访28个月无复发。结论：该病例强调了在非典型部位考虑血管球瘤的重要性，并强调了综合诊断方法以防止误诊的必要性。手术切除仍然是主要的治疗方法，建议延长术后监测以监测复发。

{"title":"Glomus Tumor in the Left Submandibular Region: A Rare Case Report and Literature Review","authors":"Huan Liu, Chengyao Zhu","doi":"10.1002/cnr2.70113","DOIUrl":"10.1002/cnr2.70113","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Glomus tumors are rare, benign mesenchymal neoplasms predominantly located in subungual regions of the extremities. Their occurrence in the mandibular region is exceptionally uncommon, presenting unique diagnostic challenges. Only a limited number of submandibular glomus tumors have been documented, leaving their presentation and management largely underexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We presented a case of glomus tumor in the submandibular area of a 60-year-old female, which appeared as a purplish-red lesion. In the absence of characteristic symptoms such as tenderness and cold sensitivity, the lesion was initially misdiagnosed as a pigmented nevus. Histopathological analysis subsequently confirmed the diagnosis as a glomus tumor. Immunohistochemical (IHC) staining further confirmed the tumor's smooth muscle and mesenchymal origins, with positive for Vimentin, SMA, Syn, Actin, Desmin, and CD34. The patient underwent surgical tumor excision with no recurrence after 28 months of follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case underscores the importance of considering glomus tumors in atypical locations and highlights the need for a comprehensive diagnostic approach to prevent misdiagnosis. Surgical excision remains the primary treatment, with extended postoperative surveillance recommended to monitor for recurrence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The miRNA-mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO GEO转录组学分析人类肝细胞癌miRNA-mRNA调控网络

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-01-07 DOI: 10.1002/cnr2.70098

Razieh Heidari, Vahideh Assadollahi, Seyedeh Negar Marashi, Fatemeh Elahian, Seyed Abbas Mirzaei

Background

Bioinformatics analysis of hepatocellular carcinoma (HCC) expression profiles can aid in understanding its molecular mechanisms and identifying new targets for diagnosis and treatment.

Aim

In this study, we analyzed expression profile datasets and miRNA expression profiles related to HCC from the GEO using R software to detect differentially expressed genes (DEGs) and differentially expressed miRNAs (DEmiRs).

Methods and results

Common DEGs were identified, and a PPI network was constructed using the STRING database and Cytoscape software to identify hub genes. The reduced levels of tumor suppressor miRNAs or down regulated DEmiRs may be increased levels of oncogenes, the oncomirs or up regulated DEmiRs may be decreased levels of tumor suppressor genes in cancerous cells. According to this strategy, increased and decreased DEGs, also increased and decreased DEmiRs were selected. The multimir package was employed to predict target genes for DEmiRs then DEmiRs-hub gene network created. We identified approximately 1000 overlapping DEGs and 60 DEmiRs. Hub genes included RRM2, MELK, KIF11, KIF23, NCAPG, DLGAP5, BUB1B, AURKB, CCNB1, KIF20A, CCNA2, TTK, PBK, TOP2A, CDK1, MAD2L1, BIRC5, ASPM, CDCA8, and CENPF, all associated with significantly worse survival in HCC. miR-224, miR-24, miR-182, miRNA-1-3p, miR-30a, miR-27a, and miR-214 were identified as important DEmiRs with targeting more than six hub genes.

Conclusion

Generally, our findings offer insight into the interaction of hub genes and miRNAs in the development of HCC by bioinformatics analysis, information that may prove useful in identifying biomarkers and therapeutic targets in HCC.

背景：肝细胞癌（HCC）表达谱的生物信息学分析有助于了解其分子机制和确定诊断和治疗的新靶点。目的：在本研究中，我们使用R软件分析GEO中与HCC相关的表达谱数据集和miRNA表达谱，以检测差异表达基因（DEGs）和差异表达miRNA （DEmiRs）。方法与结果：利用STRING数据库和Cytoscape软件对中心基因进行鉴定，构建中心基因网络。肿瘤抑制mirna水平的降低或demir水平的下调可能是癌基因水平的增加，肿瘤抑制mirna水平的降低或demir水平的上调可能是癌细胞中肿瘤抑制基因水平的降低。根据该策略，选择增加和减少的deg，以及增加和减少的demir。利用multiir包预测DEmiRs的靶基因，构建DEmiRs-hub基因网络。我们确定了大约1000个重叠的deg和60个demir。枢纽基因包括RRM2、MELK、KIF11、KIF23、NCAPG、DLGAP5、BUB1B、AURKB、CCNB1、KIF20A、CCNA2、TTK、PBK、TOP2A、CDK1、MAD2L1、BIRC5、ASPM、CDCA8和CENPF，这些基因都与HCC患者的生存率显著降低相关。miR-224、miR-24、miR-182、miRNA-1-3p、miR-30a、miR-27a和miR-214被鉴定为靶向6个以上枢纽基因的重要demir。结论：总的来说，我们的研究结果通过生物信息学分析提供了枢纽基因和mirna在HCC发展过程中的相互作用，这些信息可能有助于确定HCC的生物标志物和治疗靶点。

{"title":"The miRNA-mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO","authors":"Razieh Heidari, Vahideh Assadollahi, Seyedeh Negar Marashi, Fatemeh Elahian, Seyed Abbas Mirzaei","doi":"10.1002/cnr2.70098","DOIUrl":"10.1002/cnr2.70098","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Bioinformatics analysis of hepatocellular carcinoma (HCC) expression profiles can aid in understanding its molecular mechanisms and identifying new targets for diagnosis and treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>In this study, we analyzed expression profile datasets and miRNA expression profiles related to HCC from the GEO using R software to detect differentially expressed genes (DEGs) and differentially expressed miRNAs (DEmiRs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>Common DEGs were identified, and a PPI network was constructed using the STRING database and Cytoscape software to identify hub genes. The reduced levels of tumor suppressor miRNAs or down regulated DEmiRs may be increased levels of oncogenes, the oncomirs or up regulated DEmiRs may be decreased levels of tumor suppressor genes in cancerous cells. According to this strategy, increased and decreased DEGs, also increased and decreased DEmiRs were selected. The multimir package was employed to predict target genes for DEmiRs then DEmiRs-hub gene network created. We identified approximately 1000 overlapping DEGs and 60 DEmiRs. Hub genes included RRM2, <i>MELK</i>, <i>KIF11</i>, <i>KIF23</i>, <i>NCAPG</i>, <i>DLGAP5</i>, <i>BUB1B</i>, <i>AURKB</i>, <i>CCNB1</i>, <i>KIF20A</i>, <i>CCNA2</i>, <i>TTK</i>, <i>PBK</i>, <i>TOP2A</i>, <i>CDK1</i>, <i>MAD2L1</i>, <i>BIRC5</i>, <i>ASPM</i>, <i>CDCA8</i>, and <i>CENPF</i>, all associated with significantly worse survival in HCC. miR-224, miR-24, miR-182, miRNA-1-3p, miR-30a, miR-27a, and miR-214 were identified as important DEmiRs with targeting more than six hub genes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Generally, our findings offer insight into the interaction of hub genes and miRNAs in the development of HCC by bioinformatics analysis, information that may prove useful in identifying biomarkers and therapeutic targets in HCC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PARP-1 Inhibition Increases Oxidative Stress in Ets-1-Expressing MDA-MB-231 Breast Cancer Cells

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-01-07 DOI: 10.1002/cnr2.70119

Magalie Hervieu, Arnaud J. Legrand, Emilie Floquet, Thierry Idziorek, Corentin Spriet, Didier Monté, Vincent Villeret, Marc Aumercier, Souhaila Choul-li

Background

The Ets-1 transcription factor plays a primordial role in regulating the expression of numerous genes implicated in cancer progression. In a previous study, we revealed that poly(ADP-ribose) polymerase-1 (PARP-1) inhibition by PJ-34 results in Ets-1 level increase in cells, which is related with cell death of Ets-1-expressing cancer cells.

Aims

The mechanism of the antitumor effect of PARP-1 inhibition was investigated in the Ets-1-expressing MDA-MB-231 breast cancer cells.

Methods and Results

We tested the effects of four PARP inhibitors (PARPi) (PJ-34, Veliparib, Olaparib, and Rucaparib). We first demonstrated that PARPi reduced cells growth through G2/M cell cycle arrest. Next, we evaluated PARP-1 inhibition effect on oxidative DNA damage in Ets-1-overexpressing and Ets-1-non-expressing breast cancer cells and we showed that PARPi led only Ets-1-overexpressing cells to accumulate it, which triggers the DNA damage response as revealed by the increase in the level of a panel of DNA damage-related proteins. Importantly, we demonstrated that PARPi increased reactive oxygen species (ROS), only in Ets-1-overexpressing cells and this is accompanied by upregulation of p47^phox expression, a subunit of the NAPDH oxidase (NOX).

Conclusion

These preliminary findings correlate PARPi-induced oxidative DNA damage/oxidative stress to Ets-1 expression in breast cancer cells.

{"title":"PARP-1 Inhibition Increases Oxidative Stress in Ets-1-Expressing MDA-MB-231 Breast Cancer Cells","authors":"Magalie Hervieu, Arnaud J. Legrand, Emilie Floquet, Thierry Idziorek, Corentin Spriet, Didier Monté, Vincent Villeret, Marc Aumercier, Souhaila Choul-li","doi":"10.1002/cnr2.70119","DOIUrl":"10.1002/cnr2.70119","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Ets-1 transcription factor plays a primordial role in regulating the expression of numerous genes implicated in cancer progression. In a previous study, we revealed that poly(ADP-ribose) polymerase-1 (PARP-1) inhibition by PJ-34 results in Ets-1 level increase in cells, which is related with cell death of Ets-1-expressing cancer cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The mechanism of the antitumor effect of PARP-1 inhibition was investigated in the Ets-1-expressing MDA-MB-231 breast cancer cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We tested the effects of four PARP inhibitors (PARPi) (PJ-34, Veliparib, Olaparib, and Rucaparib). We first demonstrated that PARPi reduced cells growth through G2/M cell cycle arrest. Next, we evaluated PARP-1 inhibition effect on oxidative DNA damage in Ets-1-overexpressing and Ets-1-non-expressing breast cancer cells and we showed that PARPi led only Ets-1-overexpressing cells to accumulate it, which triggers the DNA damage response as revealed by the increase in the level of a panel of DNA damage-related proteins. Importantly, we demonstrated that PARPi increased reactive oxygen species (ROS), only in Ets-1-overexpressing cells and this is accompanied by upregulation of p47<sup>phox</sup> expression, a subunit of the NAPDH oxidase (NOX).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These preliminary findings correlate PARPi-induced oxidative DNA damage/oxidative stress to Ets-1 expression in breast cancer cells.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143055795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relapse of Diffuse Large B-Cell Lymphoma as Painless Masses in the Abdominal Wall Muscles: A Rare Case Report 弥漫性大b细胞淋巴瘤复发为腹壁肌肉无痛肿块一例罕见报告。

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-01-06 DOI: 10.1002/cnr2.70114

Somar Mansour, Seif-Aldin Abdul Rahman, Majd Mansour, Ali Afif, Raghad Hasan, Nader Abdullah, Zuheir Alshehabi

Background

The most frequent type of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphoma (DLBCL). Although lymph nodes are the most commonly affected organs compromising 70% of DLBCLs, only 5% of extranodal lymphomas represent skeletal muscle involvement. Specifically, abdominal wall muscle involvement is rare and there are only a few reported cases of DLBCL with this type of muscle involvement. Painful abdominal mass was the main presenting symptom in these reported cases.

Case

We are reporting a relapsed DLBCL with abdominal wall muscle involvement in a 65-year-old male, presenting with a discomfort and heaviness sensation in the right iliac region with no associated pain.

Conclusion

A rare case of DLBCL with recurrence in the abdominal wall muscles as painless masses was reported in this case report. To our knowledge, it is considered the fourth reported in the medical literature. It shows the importance of the diagnostic process that combines imaging with histological examination and immune stains for accurate diagnosis.

背景：最常见的非霍奇金淋巴瘤（NHL）类型是弥漫性大b细胞淋巴瘤（DLBCL）。虽然淋巴结是最常见的受累器官，占dlbcl的70%，但只有5%的结外淋巴瘤累及骨骼肌。具体来说，腹壁肌肉受累是罕见的，只有少数报道的DLBCL有这种类型的肌肉受累。疼痛的腹部肿块是主要的表现症状在这些报告的病例。病例：我们报告一例复发的DLBCL并累及腹壁肌肉，患者为65岁男性，表现为右侧髂区不适和沉重感，无相关疼痛。结论：本文报告了一例罕见的DLBCL腹壁肌无痛性肿块复发病例。据我们所知，这是医学文献中报道的第四例。它显示了诊断过程的重要性，结合影像学与组织学检查和免疫染色准确诊断。

{"title":"Relapse of Diffuse Large B-Cell Lymphoma as Painless Masses in the Abdominal Wall Muscles: A Rare Case Report","authors":"Somar Mansour, Seif-Aldin Abdul Rahman, Majd Mansour, Ali Afif, Raghad Hasan, Nader Abdullah, Zuheir Alshehabi","doi":"10.1002/cnr2.70114","DOIUrl":"10.1002/cnr2.70114","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The most frequent type of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphoma (DLBCL). Although lymph nodes are the most commonly affected organs compromising 70% of DLBCLs, only 5% of extranodal lymphomas represent skeletal muscle involvement. Specifically, abdominal wall muscle involvement is rare and there are only a few reported cases of DLBCL with this type of muscle involvement. Painful abdominal mass was the main presenting symptom in these reported cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We are reporting a relapsed DLBCL with abdominal wall muscle involvement in a 65-year-old male, presenting with a discomfort and heaviness sensation in the right iliac region with no associated pain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A rare case of DLBCL with recurrence in the abdominal wall muscles as painless masses was reported in this case report. To our knowledge, it is considered the fourth reported in the medical literature. It shows the importance of the diagnostic process that combines imaging with histological examination and immune stains for accurate diagnosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mutation Analysis of ASXL1 in Normal Karyotype Myelodysplastic Syndromes: Experience From Pakistan 正常核型骨髓增生异常综合征中 ASXL1 的突变分析：巴基斯坦的经验

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-12-29 DOI: 10.1002/cnr2.70078

Sumera Shaikh, Nida Anwar, Saba Shahid, Shamim Mushtaq, Naveena Fatima, Saima Siddiqui, Qammar Jammal

Background

The challenges in advancing treatment modalities for myelodysplastic syndromes (MDS) may stem from an incomplete understanding of the disease's complex pathophysiology and lack of reliable prognostic molecular markers. Advanced genomic techniques have revolutionized disease prognosis and risk stratification, particularly for cases with a normal karyotype.

Aim

The present study aimed to analyze ASXL1 mutations in MDS exhibiting a normal karyotype.

Methods and Results

The study enrolled 41 MDS patients with normal karyotypes. Genomic DNA was extracted from peripheral blood samples, followed by Sanger sequencing. The Chi-square and Mann–Whitney U tests were applied to assess the association of age and hemogram with the occurrence of mutations. Survival analysis was done via the Kaplan–Meier method. Statistical operations were performed employing the IBM SPSS Statistics version 24. The patients had a median age of 40 years comprising 28 (68.3%) males and 13 (31.7%) females. ASXL1 mutations were identified in 8 (19.5%), particularly stopgain single nucleotide variant (SNV) and frameshift insertion. The median total leucocyte count × 10⁹/L and blast percentage among the patients with ASXL1 mutation were 3.9 and 4.5, respectively. A survival of 85 weeks was recorded for ASXL1-mutated and nonmutated cases. The association of ASXL1 mutation status with age and studied hematological parameters was found nonsignificant.

Conclusion

ASXL1 mutation plays a pivotal role in MDS prognosis, warranting assessment at diagnosis for risk stratification and treatment decisions. Early identification of ASXL1 mutation, particularly in low-risk patients or those with normal karyotype, is imminent to identify patients exhibiting unfavorable prognosis. Integrating molecular insights into existing risk assessment holds significance for improved clinical outcomes, reduction in disease progression, and ultimately the improved quality of life and should be identified early in the course of disease even in the developing world.

{"title":"Mutation Analysis of ASXL1 in Normal Karyotype Myelodysplastic Syndromes: Experience From Pakistan","authors":"Sumera Shaikh, Nida Anwar, Saba Shahid, Shamim Mushtaq, Naveena Fatima, Saima Siddiqui, Qammar Jammal","doi":"10.1002/cnr2.70078","DOIUrl":"https://doi.org/10.1002/cnr2.70078","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The challenges in advancing treatment modalities for myelodysplastic syndromes (MDS) may stem from an incomplete understanding of the disease's complex pathophysiology and lack of reliable prognostic molecular markers. Advanced genomic techniques have revolutionized disease prognosis and risk stratification, particularly for cases with a normal karyotype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The present study aimed to analyze ASXL1 mutations in MDS exhibiting a normal karyotype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The study enrolled 41 MDS patients with normal karyotypes. Genomic DNA was extracted from peripheral blood samples, followed by Sanger sequencing. The Chi-square and Mann–Whitney <i>U</i> tests were applied to assess the association of age and hemogram with the occurrence of mutations. Survival analysis was done via the Kaplan–Meier method. Statistical operations were performed employing the IBM SPSS Statistics version 24. The patients had a median age of 40 years comprising 28 (68.3%) males and 13 (31.7%) females. ASXL1 mutations were identified in 8 (19.5%), particularly stopgain single nucleotide variant (SNV) and frameshift insertion. The median total leucocyte count × 10<sup>9</sup>/L and blast percentage among the patients with ASXL1 mutation were 3.9 and 4.5, respectively. A survival of 85 weeks was recorded for ASXL1-mutated and nonmutated cases. The association of ASXL1 mutation status with age and studied hematological parameters was found nonsignificant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ASXL1 mutation plays a pivotal role in MDS prognosis, warranting assessment at diagnosis for risk stratification and treatment decisions. Early identification of ASXL1 mutation, particularly in low-risk patients or those with normal karyotype, is imminent to identify patients exhibiting unfavorable prognosis. Integrating molecular insights into existing risk assessment holds significance for improved clinical outcomes, reduction in disease progression, and ultimately the improved quality of life and should be identified early in the course of disease even in the developing world.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short-Term Urinary Incontinence After Radical Prostatectomy Is Still Based on Patients' Age, Nerve-Sparing Approach, and Surgical-Experience, Despite the Higher-Use of Robotic Surgery in 2022 Compared to 2016 Real-World Results of a Large Rehabilitation Center in Germany 尽管2022年机器人手术的使用率高于2016年德国一家大型康复中心的实际结果，但根治性前列腺切除术后的短期尿失禁仍然取决于患者的年龄、神经保留方法和手术经验。

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-12-28 DOI: 10.1002/cnr2.70092

Lukas Püllen, Max Naumann, Ulrich Krafft, Felix Püllen, Osama Mahmoud, Mulham Al-Nader, Christopher Darr, Hendrik Borgmann, Christoph Briel, Boris Hadaschik, Johannes Salem, Timur Kuru

Background

Despite constant improvements, incontinence is one of the most relevant and quality-of-life-reducing side effects of radical prostatectomy (RP) and, in addition to patient-specific factors such as age, the experience of the surgeon/center and the surgical technique used play an important role.

Aims

To present current real-world data on short-term incontinence after RP from one of the largest German rehabilitation centers in 2022 and to compare it to the results from the same institution in 2016.

Methods and Results

Retrospective, unicentric, univariate analysis of data from 1394 men after RP in 2022 on admission and discharge from the rehabilitation clinic. Incontinence defined as ≥ 1 pad/day was evaluated by quantitative measuring all day incontinence under a defined graduation and compared to the results of 2016. Totally, 1393 men were available for analysis in 2022 compared to 1390 in 2016. Median age for both cohorts was 66 years with minor differences in preoperative PSA levels. Despite different surgical approaches, no significant change in short-term incontinence rates in 2016 and 2022 were noted at discharge (76.9% vs. 77.9%, p = 0.56). A notable increase in patients with ISUP grade Group 2 and a shift towards robotic surgery were observed in 2022 (45.5%–71%). While nerve sparing led to a significant improvement in continence (p < 0.01), lymphadenectomy and T-stage were not related to any significant increase in short-term incontinence rates. Comparing age groups within the cohort, patients > 69 years exhibited the highest risk of short-term incontinence and least likelihood of regaining continence during rehabilitation (p < 0.01). Men treated at a certified prostate cancer center had significantly (p < 0.01) lower short-term incontinence rates.

Conclusion

Our study shows little improvement in short-term postoperative incontinence rates after RP in Germany in the last 6 years and known risk factors for postoperative incontinence like age, nerve-sparing surgery, and level of experience were reproduced in our analyses. We conclude not only to carefully select but also to counsel patients before being treated for prostate cancer and to strongly advice treatment at certified centers.

背景：尽管不断改善，尿失禁是根治性前列腺切除术（RP）中最相关的和降低生活质量的副作用之一，除了患者的特定因素，如年龄，外科医生/中心的经验和所使用的手术技术也起着重要作用。目的：展示2022年德国最大的康复中心之一RP后短期尿失禁的当前真实数据，并将其与2016年同一机构的结果进行比较。方法与结果：回顾性、单中心、单变量分析2022年1394例男性RP患者入院和出院时的资料。以尿失禁≥1 pad/d为标准，定量测量确定毕业后的全天尿失禁情况，并与2016年的结果进行比较。2022年共有1393名男性可用于分析，而2016年为1390名。两组患者的中位年龄均为66岁，术前PSA水平差异较小。尽管手术方式不同，但2016年和2022年出院时短期尿失禁率没有显著变化（76.9%对77.9%,p = 0.56）。2022年，ISUP级第2组患者显著增加，转向机器人手术（45.5%-71%）。尽管神经保留导致了尿失禁的显著改善（p69），但术后短期尿失禁的风险最高，康复期间恢复尿失禁的可能性最小(p结论：我们的研究显示，在过去的6年里，德国RP术后短期尿失禁率几乎没有改善，我们的分析重现了已知的术后尿失禁的危险因素，如年龄、神经保留手术和经验水平。我们的结论是，不仅要仔细选择，而且要在前列腺癌治疗前对患者进行咨询，并强烈建议在认证中心进行治疗。

{"title":"Short-Term Urinary Incontinence After Radical Prostatectomy Is Still Based on Patients' Age, Nerve-Sparing Approach, and Surgical-Experience, Despite the Higher-Use of Robotic Surgery in 2022 Compared to 2016 Real-World Results of a Large Rehabilitation Center in Germany","authors":"Lukas Püllen, Max Naumann, Ulrich Krafft, Felix Püllen, Osama Mahmoud, Mulham Al-Nader, Christopher Darr, Hendrik Borgmann, Christoph Briel, Boris Hadaschik, Johannes Salem, Timur Kuru","doi":"10.1002/cnr2.70092","DOIUrl":"10.1002/cnr2.70092","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite constant improvements, incontinence is one of the most relevant and quality-of-life-reducing side effects of radical prostatectomy (RP) and, in addition to patient-specific factors such as age, the experience of the surgeon/center and the surgical technique used play an important role.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To present current real-world data on short-term incontinence after RP from one of the largest German rehabilitation centers in 2022 and to compare it to the results from the same institution in 2016.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Retrospective, unicentric, univariate analysis of data from 1394 men after RP in 2022 on admission and discharge from the rehabilitation clinic. Incontinence defined as ≥ 1 pad/day was evaluated by quantitative measuring all day incontinence under a defined graduation and compared to the results of 2016. Totally, 1393 men were available for analysis in 2022 compared to 1390 in 2016. Median age for both cohorts was 66 years with minor differences in preoperative PSA levels. Despite different surgical approaches, no significant change in short-term incontinence rates in 2016 and 2022 were noted at discharge (76.9% vs. 77.9%, <i>p</i> = 0.56). A notable increase in patients with ISUP grade Group 2 and a shift towards robotic surgery were observed in 2022 (45.5%–71%). While nerve sparing led to a significant improvement in continence (<i>p</i> < 0.01), lymphadenectomy and T-stage were not related to any significant increase in short-term incontinence rates. Comparing age groups within the cohort, patients > 69 years exhibited the highest risk of short-term incontinence and least likelihood of regaining continence during rehabilitation (<i>p</i> < 0.01). Men treated at a certified prostate cancer center had significantly (<i>p</i> < 0.01) lower short-term incontinence rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study shows little improvement in short-term postoperative incontinence rates after RP in Germany in the last 6 years and known risk factors for postoperative incontinence like age, nerve-sparing surgery, and level of experience were reproduced in our analyses. We conclude not only to carefully select but also to counsel patients before being treated for prostate cancer and to strongly advice treatment at certified centers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report 恩科非尼联合比尼美替尼治疗并发BRAFV600E和KRASG12R突变的厄德海姆- chester病的疗效：1例报告

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-12-26 DOI: 10.1002/cnr2.70093

Yuto Hibino, Rika Sakai, Hiroyuki Takahashi, Takaaki Takeda, Natsuki Hirose, Mayumi Tokunaga, Kota Washimi, Tomoyuki Yokose, Rika Kasajima, Yukihiko Hiroshima, Yohei Miyagi, Hideaki Nakajima

Background

Erdheim–Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis with diverse clinical manifestations, often associated with mutations in the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway. BRAF and KRAS mutations, which are driver mutations of oncogenes, participate in the same signaling pathway (MAPK/ERK pathway) and are usually mutually exclusive. We report a case of ECD with concurrent BRAF^V600E and KRAS^G12R mutations treated using BRAF and MEK inhibitors.

Case

A 70-year-old man was referred to our hospital with a mesenteric nodal lesion on computed tomography scan. The patient experienced symptoms consistent with ECD, including central diabetes insipidus. Biopsy revealed histiocytes positive for CD68 and CD163, negative for S100, CD1a, and CD21. Liquid-based comprehensive genomic profiling and tissue-based cancer gene panel test identified BRAF^V600E and KRAS^G12R mutations with different variant allele fraction. Additional immunohistochemistry with an antibody specific to mutant BRAF^V600E protein stained some proliferating histiocytes, consistent with ECD. Based on the genomic profiling results, we hypothesized that there was a coexistence of a clone harboring BRAF^V600E and another clone harboring KRAS^G12R, and planned a combination therapy with BRAF and MEK inhibitors targeting each clone, respectively. The patient received oral encorafenib at 100 mg once daily and oral binimetinib at 15 mg twice daily. The combination therapy resulted in rapid resolution of symptoms and significant improvement in imaging findings.

Conclusion

This case represents a unique presentation of ECD with concurrent BRAF^V600E and KRAS^G12R mutations. Combination therapy with encorafenib and binimetinib targeting each clone resulted in a remarkable therapeutic effect and was well-tolerated. This is the first reported case of ECD treated with encorafenib and binimetinib. The combination therapy with BRAF and MEK inhibitors is one of the rational treatment options for cases of ECD with a suspicion of multiple clones.

背景：Erdheim-Chester病（ECD）是一种罕见的非朗格汉斯细胞组织细胞增多症，具有多种临床表现，通常与丝裂原活化蛋白激酶/细胞外信号调节激酶（MAPK/ERK）通路突变有关。BRAF和KRAS突变是致癌基因的驱动突变，参与相同的信号通路（MAPK/ERK通路），通常是互斥的。我们报告了一例并发BRAFV600E和KRASG12R突变的ECD，使用BRAF和MEK抑制剂治疗。病例：一名70岁男性在计算机断层扫描中发现肠系膜结节病变。患者的症状与ECD一致，包括中枢性尿崩症。活检显示组织细胞CD68和CD163阳性，S100、CD1a和CD21阴性。基于液体的综合基因组分析和基于组织的癌症基因面板检测发现BRAFV600E和KRASG12R突变具有不同的变异等位基因分数。突变BRAFV600E蛋白特异性抗体的额外免疫组化染色了一些增殖组织细胞，与ECD一致。基于基因组分析结果，我们假设存在一个携带BRAFV600E的克隆和另一个携带KRASG12R的克隆共存，并计划分别针对每个克隆使用BRAF和MEK抑制剂联合治疗。患者口服恩可非尼100mg，每日一次，口服比尼美替尼15mg，每日两次。联合治疗导致症状迅速缓解，影像学表现显著改善。结论：该病例是一种独特的伴有BRAFV600E和KRASG12R突变的ECD。针对每个克隆使用恩科非尼和比尼美替尼联合治疗产生了显著的治疗效果，并且耐受性良好。这是首次报道的使用恩可非尼和比尼替尼治疗ECD的病例。BRAF和MEK抑制剂联合治疗是怀疑多克隆ECD病例的合理治疗选择之一。

{"title":"Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report","authors":"Yuto Hibino, Rika Sakai, Hiroyuki Takahashi, Takaaki Takeda, Natsuki Hirose, Mayumi Tokunaga, Kota Washimi, Tomoyuki Yokose, Rika Kasajima, Yukihiko Hiroshima, Yohei Miyagi, Hideaki Nakajima","doi":"10.1002/cnr2.70093","DOIUrl":"10.1002/cnr2.70093","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Erdheim–Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis with diverse clinical manifestations, often associated with mutations in the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway. <i>BRAF</i> and <i>KRAS</i> mutations, which are driver mutations of oncogenes, participate in the same signaling pathway (MAPK/ERK pathway) and are usually mutually exclusive. We report a case of ECD with concurrent <i>BRAF</i><sup>V600E</sup> and <i>KRAS</i><sup>G12R</sup> mutations treated using BRAF and MEK inhibitors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 70-year-old man was referred to our hospital with a mesenteric nodal lesion on computed tomography scan. The patient experienced symptoms consistent with ECD, including central diabetes insipidus. Biopsy revealed histiocytes positive for CD68 and CD163, negative for S100, CD1a, and CD21. Liquid-based comprehensive genomic profiling and tissue-based cancer gene panel test identified <i>BRAF</i><sup>V600E</sup> and <i>KRAS</i><sup>G12R</sup> mutations with different variant allele fraction. Additional immunohistochemistry with an antibody specific to mutant <i>BRAF</i><sup>V600E</sup> protein stained some proliferating histiocytes, consistent with ECD. Based on the genomic profiling results, we hypothesized that there was a coexistence of a clone harboring <i>BRAF</i><sup>V600E</sup> and another clone harboring <i>KRAS</i><sup>G12R</sup>, and planned a combination therapy with BRAF and MEK inhibitors targeting each clone, respectively. The patient received oral encorafenib at 100 mg once daily and oral binimetinib at 15 mg twice daily. The combination therapy resulted in rapid resolution of symptoms and significant improvement in imaging findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case represents a unique presentation of ECD with concurrent <i>BRAF</i><sup>V600E</sup> and <i>KRAS</i><sup>G12R</sup> mutations. Combination therapy with encorafenib and binimetinib targeting each clone resulted in a remarkable therapeutic effect and was well-tolerated. This is the first reported case of ECD treated with encorafenib and binimetinib. The combination therapy with BRAF and MEK inhibitors is one of the rational treatment options for cases of ECD with a suspicion of multiple clones.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Comparative Meta-Analysis on the Association of lncRNAs MALAT1, HOTAIR, and AFAP1-AS1 With the Risk of Developing Lymph Node Metastasis in Lung Cancer lncrna MALAT1、HOTAIR和AFAP1-AS1与肺癌淋巴结转移风险相关性的比较meta分析

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-12-26 DOI: 10.1002/cnr2.70091

Anha Tasnim, Afra Anjum Sumaiya, Abdullah Al Noman, Anika Tahsin, Abdullah Al Saba, Rubaiat Ahmed, Tahirah Yasmin, A. H. M. Nurun Nabi

Background

Numerous studies have demonstrated the significance of long noncoding RNA (lncRNA) in the development of cancer metastasis. The expression levels of many lncRNAs are elevated in metastatic lung cancer patients compared to non-metastatic lung cancer patients.

Objectives

The primary objective of the study was to investigate the association between the expression levels of three lncRNAs (MALAT1, HOTAIR, and AFAP1-AS1) and lymph node metastasis (LNM) of lung cancer.

Methods

Cell Press, PubMed, SpringerLink, Web of Science, and Google Scholar were explored to perform the literature search. After screening 1862 articles, 66 English-language articles were selected based on the inclusion and exclusion criteria. From those articles, 17 publications comprising 1622 lung cancer patients were chosen for statistical analyses as well as quality assessment tests.

Results

Forest plot analysis revealed that there was a significant difference in the incidence of LNM between the high and low MALAT1 expression groups (OR = 3.21, 95% CI: 1.34–7.67; random effects model). Significant differences were also observed in the incidence of LNM between patients with high and low HOTAIR expression levels (OR = 4.17, 95% CI: 1.47–11.82; random effects model). The expression level of AFAP1-AS1 was found to be significantly associated with LNM in lung cancer (OR = 2.31, 95% CI: 1.39–3.85, random effects model). Additional analysis from GEPIA and GEO databases revealed that the expression levels of these lncRNAs vary according to the type of tumor tissue, organ of metastasis, and cancer stage. However, these databases show that the result for AFAP1-AS1 is the most aligned with the meta-analysis's findings. Furthermore, several quality assessment tests showed that the AFAP1-AS1 studies are more reliable compared to the studies of other lncRNAs.

Conclusion

This study suggested that LNM in lung cancer patients is associated mostly with an elevated AFAP1-AS1 lncRNA level among the pool of three lncRNAs analyzed. Before these results can be implemented in a clinical setting, it is essential to conduct further validation and undertake comprehensive analysis to ensure robustness and reliability.

背景：大量研究已经证实长链非编码RNA （lncRNA）在肿瘤转移过程中的重要作用。与非转移性肺癌患者相比，许多lncrna在转移性肺癌患者中的表达水平升高。目的：本研究的主要目的是探讨三种lncRNAs （MALAT1、HOTAIR和AFAP1-AS1）的表达水平与肺癌淋巴结转移（LNM）之间的关系。方法：利用Cell Press、PubMed、SpringerLink、Web of Science、谷歌Scholar等数据库进行文献检索。在对1862篇文章进行筛选后，根据纳入和排除标准筛选出66篇英文文章。从这些文章中，选择了17份出版物，包括1622名肺癌患者，进行统计分析和质量评估测试。结果：森林样图分析显示，MALAT1高表达组和低表达组之间LNM的发生率有显著差异(OR = 3.21, 95% CI: 1.34-7.67；随机效应模型)。HOTAIR高表达水平和低表达水平患者的LNM发生率也有显著差异(OR = 4.17, 95% CI: 1.47-11.82；随机效应模型)。AFAP1-AS1表达水平与肺癌LNM有显著相关性（OR = 2.31, 95% CI: 1.39 ~ 3.85，随机效应模型）。来自GEPIA和GEO数据库的进一步分析显示，这些lncrna的表达水平根据肿瘤组织类型、转移器官和癌症分期而变化。然而，这些数据库显示，AFAP1-AS1的结果与荟萃分析的结果最一致。此外，一些质量评估试验表明，与其他lncrna的研究相比，AFAP1-AS1的研究更可靠。结论：本研究提示，在分析的3种lncRNA中，肺癌患者LNM主要与AFAP1-AS1 lncRNA水平升高相关。在这些结果可以在临床环境中实施之前，有必要进行进一步的验证并进行全面的分析，以确保稳健性和可靠性。

{"title":"A Comparative Meta-Analysis on the Association of lncRNAs MALAT1, HOTAIR, and AFAP1-AS1 With the Risk of Developing Lymph Node Metastasis in Lung Cancer","authors":"Anha Tasnim, Afra Anjum Sumaiya, Abdullah Al Noman, Anika Tahsin, Abdullah Al Saba, Rubaiat Ahmed, Tahirah Yasmin, A. H. M. Nurun Nabi","doi":"10.1002/cnr2.70091","DOIUrl":"10.1002/cnr2.70091","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Numerous studies have demonstrated the significance of long noncoding RNA (lncRNA) in the development of cancer metastasis. The expression levels of many lncRNAs are elevated in metastatic lung cancer patients compared to non-metastatic lung cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The primary objective of the study was to investigate the association between the expression levels of three lncRNAs (MALAT1, HOTAIR, and AFAP1-AS1) and lymph node metastasis (LNM) of lung cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cell Press, PubMed, SpringerLink, Web of Science, and Google Scholar were explored to perform the literature search. After screening 1862 articles, 66 English-language articles were selected based on the inclusion and exclusion criteria. From those articles, 17 publications comprising 1622 lung cancer patients were chosen for statistical analyses as well as quality assessment tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forest plot analysis revealed that there was a significant difference in the incidence of LNM between the high and low MALAT1 expression groups (OR = 3.21, 95% CI: 1.34–7.67; random effects model). Significant differences were also observed in the incidence of LNM between patients with high and low HOTAIR expression levels (OR = 4.17, 95% CI: 1.47–11.82; random effects model). The expression level of AFAP1-AS1 was found to be significantly associated with LNM in lung cancer (OR = 2.31, 95% CI: 1.39–3.85, random effects model). Additional analysis from GEPIA and GEO databases revealed that the expression levels of these lncRNAs vary according to the type of tumor tissue, organ of metastasis, and cancer stage. However, these databases show that the result for AFAP1-AS1 is the most aligned with the meta-analysis's findings. Furthermore, several quality assessment tests showed that the AFAP1-AS1 studies are more reliable compared to the studies of other lncRNAs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study suggested that LNM in lung cancer patients is associated mostly with an elevated AFAP1-AS1 lncRNA level among the pool of three lncRNAs analyzed. Before these results can be implemented in a clinical setting, it is essential to conduct further validation and undertake comprehensive analysis to ensure robustness and reliability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0